Skip to content

A prospective cohort study of Lingbao Heart Pill in the treatment of stable coronary heart disease (qi deficiency and blood stasis)

A prospective cohort study of Lingbao Heart Pill in the treatment of stable coronary heart disease (qi deficiency and blood stasis)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070975
Enrollment
Unknown
Registered
2023-04-27
Start date
2023-04-27
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable CAD

Interventions

Lingbao Huxin Dan or Lingbao Huxin Dan conventional Western medicine treatment:None
Conventional Western medicine treatment:None

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Consistent with the diagnosis of stable coronary heart disease (CCS angina severity grade II~IV); (2) Age 18~85 years old; (3) Consistent with the diagnosis of qi deficiency and blood stasis in traditional Chinese medicine; (4) Not combined with severe heart disease, malignant hypertension, severe heart failure, and severe arrhythmia; (5) Not combined with other diseases that cause chest pain, such as psychosis, severe neurosis, hyperthyroidism, biliary heart syndrome, gastric and esophageal reflux, aortic dissection, etc.; (6) Except for patients who the investigator believes are not suitable to participate in this study (pregnant and lactating women, patients who are participating in other projects, etc.).

Exclusion criteria

Exclusion criteria: not

Design outcomes

Primary

MeasureTime frame
Efficacy of angina symptoms;

Secondary

MeasureTime frame
CCS Class;Seattle angina scale score;Number of attacks in angina months (every 4 weeks);Average duration of angina attacks (months/(every 4 weeks);Average VAS score of angina pain (monthly/(every 4 weeks);Monthly (every 4 weeks) nitroglycerin usage;Change Value and change rate of TCM syndrome;

Countries

China

Contacts

Public ContactZhu Mingjun

The First Affiliated Hospital of Henan University of Chinese Medicine

zhumingjun317@163.com+86 13903846672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026